THE World Health Organisation said Friday it "strongly recommended" Pfizer's COVID-19 antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalisation.
However the UN agency warned it was "extremely concerned" that the inequality in access seen with COVID vaccines would again leave low- and middle-income countries "pushed to the end of the queue".
US pharma giant Pfizer's combination of nirmatrelvir and ritonavir was the "superior choice" of treatment for unvaccinated, elderly or immunocompromised people with COVID, the WHO's experts said in the BMJ medical journal.
For the same patients, the WHO also made a "conditional (weak) recommendation" of the antiviral drug remdesivir made by US biotech firm Gilead -- which it had previously recommended against.
The WHO recommended Paxlovid over remdesivir, as well as over Merck's molnupiravir pill and monoclonal antibodies.
Pfizer's oral treatment prevents hospitalisation more than the "available alternatives, has fewer concerns with respects to harms than molnupiravir, and is easier to administer than intravenous remdesivir and antibodies," the WHO's experts said.
The new recommendation was based on the findings of two trials involving almost 3,100 patients which showed that Paxlovid reduced the risk of hospital admission by 85 percent.
The trials also "suggested no important difference in mortality" and "little or no risk of adverse effects leading to drug discontinuation".
The recommendation applies to people over the age of 18, but not to pregnant or breastfeeding women.
It also does not apply to patients with a low risk of complications from the disease, because the benefit would be minimal.
The WHO's experts also declined to give an opinion for patients with severe forms of the disease, due to a lack of data.
- Limitations and inequities -
The WHO stressed the limitations of such antiviral treatments.
"The medicine can only be administered while the disease is at its early stages," they said.
This means the patients must quickly test positive and be prescribed the pill by a doctor -- all of which can pose obstacles for low- and middle-income countries, the WHO said.
Yet Covid pills have been seen as a potentially huge step in ending the pandemic as they can be taken at home, rather than in hospital.
Patients must start taking their Paxlovid pills within five days of the onset of symptoms -- the course then lasts five days.
Remdesivir can be taken within seven days of symptoms setting in, but it is administered intravenously over three days.
- Questions about cost -
The WHO called on Pfizer to "make its pricing and deals more transparent" for Paxlovid.
Lisa Hedman, the WHO's senior advisor on access to medicines, said that radio station NPR reported a full course of Paxlovid costs $530 in the United States. Another source unconfirmed by WHO gave the price of $250 in an upper-middle income country.
Remdesivir meanwhile costs $520, Hedman said, but generic versions made by companies in India sell for $53-$64.
There is also a question mark over whether the virus could build resistance to these treatments.
But earlier this month Pfizer CEO Albert Bourla predicted a bright future for treatments like Paxlovid as people grow tired of getting further booster vaccinations.
Coming under fire for prioritising wealthy countries with its vaccine, Pfizer has agreed to allow some generic drugmakers around the world to make cheaper versions of Paxlovid under a UN-backed scheme.
But on Friday the WHO "strongly recommended" that Pfizer let more generic manufacturers produce the drug and "make it available faster at affordable prices".
ETX Studio
Fri Apr 22 2022
![WHO 'strongly recommends' Pfizer's COVID pill WHO 'strongly recommends' Pfizer's COVID pill](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-11/51636156278_Paxlovid.jpg)
The WHO recommended Paxlovid over remdesivir, as well as over Merck's molnupiravir pill and monoclonal antibodies. -Facebook/Piguka wiata
PAC beri tempoh tiga bulan kepada HRD Corp
Jawatankuasa Kira-kira Wang Negara (PAC) memberi tempoh tiga bulan kepada Perbadanan Pembangunan Sumber Manusia (HRD Corp) untuk mengemukakan laporan tindakan susulan terhadap syor jawatankuasa itu.
Kylian Mbappe tandatangan kontrak dengan Real Madrid
Bintang bola sepak Perancis Kylian Mbappe menandatangani kontrak selama lima tahun dengan kelab Sepanyol Real Madrid pada Selasa.
Pelepasan ketujuh air sisa nuklear Fukushima ke laut selesai
Jepun telah menyelesaikan pusingan ketujuh pelepasan air sisa radioaktif yang dirawat dari loji kuasa nuklear Fukushima Daiichi ke Lautan Pasifik pada Selasa.
Empat termasuk kapten maut dalam pertempuran
Empat anggota tentera India termasuk kapten meninggal dunia akibat kecederaan selepas pertempuuran pada malam isnin di Hutan Desa.
Pakistan sahkan 4 warganya terbunuh di Oman
Pakistan berkata pada Selasa empat warganya terbunuh dalam insiden tembakan pada malam Isnin berhampiran ibu negara Oman, Muscat.
Lima terbunuh, puluhan cedera dalam protes antikuota di Bangladesh
Sekurang-kurangnya empat orang terbunuh dan puluhan lagi cedera dalam pertempuran antara pelajar yang memprotes sistem kuota dalam pekerjaan sektor awam dan polis di pelbagai bahagian Bangladesh pada Selasa.
Kerajaan cadang perkenal pembiayaan swasta
Kerajaan menyasarkan untuk memperkenalkan pembiayaan swasta alternatif bagi memastikan kemampanan kewangan program sektor air, sekali gus mengurangkan kebergantungan pada perbelanjaan kerajaan dan mengukuhkan daya tahan.
Saya tak fitnah Guan Eng, cuma jelaskan siasatan SPRM - Muhyiddin
Presiden Bersatu Tan Sri Muhyiddin Yassin memberitahu Mahkamah Tinggi Kuala Lumpur hari ini bahawa beliau tidak memfitnah Lim Guan Eng berhubung isu pengecualian cukai terhadap Yayasan Albukhary
KPT alu-alukan dapatan, cadangan PAC - Zambry
Ini termasuklah cadangan pelaksanaan Garis Panduan Pelaburan dan Pembiayaan oleh Universiti Awam 2024 kepada anak-anak syarikat di bawah seliaan Kementerian Pendidikan Tinggi (KPT).
Lebih 340,000 syarikat buat transaksi serah simpan maklumat pemunyaan benefisial
Sebanyak 340,637 syarikat telah membuat transaksi serah simpan maklumat pemunyaan benefisial (beneficial ownership) bagi tempoh 1 April hingga 14 Julai lepas.
![Ubat Paxlovid masih berkesan rawat COVID-19 Ubat Paxlovid masih berkesan rawat COVID-19](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2023-10/61696481353_MuhammadRadzi.jpg)
Ubat Paxlovid masih berkesan rawat COVID-19
Rawatan antiviral itu boleh mengurangkan gejala COVID-19 dan mengelakkan penyakit daripada menjadi lebih teruk.
![Vaksinasi, ubat antiviral strategi tangani gelombang baharu COVID-19 - Khairy Vaksinasi, ubat antiviral strategi tangani gelombang baharu COVID-19 - Khairy](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2022-06/41654690954_KhairyJamaludin.jpg)
Vaksinasi, ubat antiviral strategi tangani gelombang baharu COVID-19 - Khairy
Masih terdapat lebih 30 peratus golongan dewasa di negara ini yang belum mendapatkan dos penggalak setakat 7 Julai.
![Pfizer dakwa pil COVID-19 keluarannya mampu kurangkan kemasukan ke hospital Pfizer dakwa pil COVID-19 keluarannya mampu kurangkan kemasukan ke hospital](https://resizer-awani.eco.astro.com.my/tr:w-177,h-100,q-100,f-auto/https://img.astroawani.com/2021-11/51636156278_Paxlovid.jpg)
Pfizer dakwa pil COVID-19 keluarannya mampu kurangkan kemasukan ke hospital
Pfizer menamatkan ujian klinikal ke atas Paxlovid, susulan keputusan awal yang sangat positif.